-
1.
公开(公告)号:US20230278965A1
公开(公告)日:2023-09-07
申请号:US18011469
申请日:2021-06-18
发明人: Ae Nim PAE , Yun Kyung KIM , Sang Min LIM , Sungsu LIM , Haeun LEE , Woo Seung SON , Hye Yeon LEE
IPC分类号: C07D241/24 , C07D213/75 , C07D401/14 , C07D409/12 , C07D417/12 , C07D413/12 , C07D237/08 , C07D333/60 , C07D277/56
CPC分类号: C07D241/24 , C07D213/75 , C07D401/14 , C07D409/12 , C07D417/12 , C07D413/12 , C07D237/08 , C07D333/60 , C07D277/56
摘要: Provided are novel carbonohydrazonoyl dicyanide compounds including two or more aryl or heteroaryl groups connected via a linker and uses thereof.
-
公开(公告)号:US20230278963A1
公开(公告)日:2023-09-07
申请号:US18011460
申请日:2021-06-18
发明人: Ae Nim PAE , Yun Kyung KIM , Sang Min LIM , Sungsu LIM , Haeun LEE , Woo Seung SON , Hye Yeon LEE
IPC分类号: C07D237/14
CPC分类号: C07D237/14
摘要: Provided are novel oxopyridazinyl-phenyl-carbonohydrazonoyl dicyanide compounds and uses thereof.
-
公开(公告)号:US20130123599A1
公开(公告)日:2013-05-16
申请号:US13670957
申请日:2012-11-07
发明人: Il Joo CHO , Eui Sung YOON , Jei Won CHO , Myoung Gun JEON , Yun Kyung KIM
IPC分类号: A61B5/0478
CPC分类号: A61B5/0478 , A61B5/6868 , A61B2503/40 , A61B2503/42 , A61B2562/125 , A61B2562/18
摘要: The micro probe according to an embodiment of the present disclosure includes: a probe portion made of a rigid material and serving as a portion inserted into the brain; a flexible portion connected to a distal end of the probe portion and made of a flexible material; a soluble portion coated on at least one surface of the flexible portion and made of a material which is dissolved by a solution in the cranium; and a body portion connected to the other end of the flexible portion whose one end is connected to the probe portion.
摘要翻译: 根据本公开的实施例的微型探针包括:由刚性材料制成并用作插入脑中的部分的探针部分; 柔性部分,其连接到探针部分的远端并由柔性材料制成; 所述可溶部分涂覆在所述柔性部分的至少一个表面上,并且由溶液溶解在所述颅骨中的材料制成; 以及主体部分,其连接到柔性部分的另一端,其一端连接到探针部分。
-
公开(公告)号:US20230295095A1
公开(公告)日:2023-09-21
申请号:US18011459
申请日:2021-06-18
发明人: Ae Nim PAE , Yun Kyung KIM , Sang Min LIM , Sungsu LIM , Haeun LEE , Woo Seung SON , Hye Yeon LEE
IPC分类号: C07D217/24 , C07D235/26 , C07D263/58 , C07D277/68 , C07D215/227 , C07D471/04
CPC分类号: C07D217/24 , C07D235/26 , C07D263/58 , C07D277/68 , C07D215/227 , C07D471/04
摘要: Provided are novel fused-heterocyclyl-carbonohydrazonoyl dicyanide compounds and uses thereof.
-
公开(公告)号:US20200340001A1
公开(公告)日:2020-10-29
申请号:US16857089
申请日:2020-04-23
发明人: Sung Su LIM , Seul Gi SHIN , Yun Kyung KIM
摘要: The present disclosure relates to a vector pair for screening TDP-43 (TAR DNA-binding protein 43 or TransActive Response DNA-binding protein 43) oligomer formation, a cell line transfected with the vector pair, and a method of monitoring TDP-43 oligomer formation using the cell line. More specifically, the vector pair includes: a first vector including a first TDP-43 gene and a first fluorescence protein gene; and a second vector including a second TDP-43 gene and a second fluorescence protein gene, wherein a protein expressed from the first fluorescence protein gene and a protein expressed from the second fluorescence protein gene bind to each other to display fluorescence, by association between a protein expressed from the first TDP-43 gene and a protein expressed from the second TDP-43 gene. The vector pair is effective in that it makes it possible to monitor TDP-43 oligomer formation in living cells.
-
公开(公告)号:US20220396553A1
公开(公告)日:2022-12-15
申请号:US17415382
申请日:2018-12-26
发明人: Ae Nim PAE , Yun Kyung KIM , Sang Min LIM , Sungsu LIM , Jihye SEONG , Jae Wook LEE , Ji Yeon SONG , Seulgi SHIN , Hyean Jeong JEONG , Woo Seung SON , Haeun LEE , Da Mi LIM , Seok Kyu KIM , Jee Yun AHN , Chae Won KIM , Ashwini Machhindra LONDHE , Lizaveta GOTINA , Hyojin KIM , Hye Yeon LEE , Nam Gyung KIM , Eunji CHA , Kunhee KIM , Ji Woong LIM
IPC分类号: C07D241/42 , C07D239/34 , C07D239/30 , C07D239/26 , C07D277/28 , C07C255/66 , C07D487/04 , C07D471/04 , C07D231/12 , C07D209/14 , C07D231/56 , C07D215/38 , C07D417/12 , C07D417/04 , C07D277/82 , C07D237/14
摘要: The present invention relates to novel hydrazone derivatives in which a terminal amine group is substituted with an aryl group or a heteroaryl group, and uses thereof.
-
公开(公告)号:US20210255203A1
公开(公告)日:2021-08-19
申请号:US17021438
申请日:2020-09-15
发明人: Ghil Soo NAM , Hyun Ah CHOO , Ahmed A. Elbatrawy , Gyo Chang KEUM , Yun Kyung KIM , Sung Su LIM , Jae Kyun LEE , Eun Kyoung BANG
IPC分类号: G01N33/68 , C07D215/20 , C07D401/06
摘要: Disclosed are a compound with near-infrared fluorescence that selectively binds to tau aggregates, a method for preparing the same, a tau-targeting near-infrared fluorescent probe including the compound, a composition for detecting a tau fiber protein containing the near-infrared fluorescent probe as an active ingredient, and the use of the composition for the diagnosis of tauopathy. In particular, the compound does not bind to an amyloid beta protein and has high selectivity to a tau aggregate, specifically reported as an etiology of the initial state of tauopathy, thus being useful as a near-infrared fluorescent detector for detecting a tau fiber protein for early diagnosis of a tauopathy including Alzheimer's disease.
-
公开(公告)号:US20170354650A1
公开(公告)日:2017-12-14
申请号:US15403404
申请日:2017-01-11
发明人: Hyunah CHOO , Sun-Joon MIN , Yun Kyung KIM , Hoon RYU , Hyemyung SEO , Juhyeon KIM , Jihoon JANG , Sungsu LIM , Younghee KIM , Yu Jin HWANG , Yong Seo CHO
IPC分类号: A61K31/47 , A61K31/4709 , A61K31/5377
CPC分类号: A61K31/47 , A61K31/4709 , A61K31/5377
摘要: The present disclosure relates to a quinoline derivative which inhibits the activity of histone methyltransferases (ESET/SETDB1) specific for the histone molecule H3K9 or a pharmaceutically acceptable salt thereof and a use thereof.
-
公开(公告)号:US20170298011A1
公开(公告)日:2017-10-19
申请号:US15516395
申请日:2015-09-24
发明人: Ki Duk PARK , ChangJoon Justin LEE , Dong Jin KIM , Ae Nim PAE , Hyun Ah CHOO , Sun Joon MIN , Yong Koo KANG , Yun Kyung KIM , Hyo Jung SONG , Ji Won CHOI , Min Ho NAM , Jun Young HEO , Seul Ki YEON , Bo Ko JANG , Eun Ji JU , Seon Mi JO , Jong-Hyun PARK
IPC分类号: C07C237/06 , C07C231/12
摘要: The present disclosure relates to an α-aminoamide derivative compound and a pharmaceutical composition containing the same. According to various embodiments of the present disclosure, provided is a therapeutic agent which can overcome the disadvantages of existing drugs used as a MAO-B inhibitor and, specifically, reversibly inhibits MAO-B through a non-covalent bond so as to alleviate or eliminate the side effects of the existing drugs which exhibit a therapeutic effect by irreversibly acting via a covalent bond with MAO-B. Particularly, a new compound having superior stability and efficacy compared to the existing reversible MAO-B inhibitors may be provided.
-
-
-
-
-
-
-
-